TABLE 3.
Summary of post-BSD intervention course and follow-up
| Author, year | Complication types | Complications (n) | Post-recovery (days) BSD vs Sx | Post-BSD care | Revision procedures (n) | Minimum follow-up (mo) |
|---|---|---|---|---|---|---|
| RCT | ||||||
| Plaza, 201116 | Synechiae, minor bleeding in both groups | NR | NR | Oral abx + steroids x 1w, saline irrigation & topical steroid x 1m, debridement q.o.w x 8w as needed | 4 (1 in hybrid, 3 in ESS) | 12 (1 LTFU in each group) |
| Achar, 201217 | None | 0 | 2.2 vs 5 | saline spray x 6w, flixonase gtt x 4w followed by flixonase/nasone spray x 6w | NR | 6 |
| Cutler, 201318 | None | 0 | NR | 1 in each arm | 6 | |
| Marzetti, 201419 | None | 0 | NR | abx suspension x10d and acetaminophen as needed | 0 | 6 |
| Hathorn, 201520 | None | 0 | NR | oral steroid x1w, budesonide nasal rinses | 0 | 12 (73% at 12 mo, all until till 3 mo) |
| Bizaki, 20169 | Infection, crusting, synechiae, bleeding, anosmia | 9 in BD vs 16 in uncinectomy | NR | NR | NR | 6 (30/30 BSD, 30/32 uncinectomy) |
| Chandra, 201621 | None | 0 | 1.7 vs 5 | NR | 1/37 rev in BD, 2/29 in FESS @ 18 mo | 24 (130/135 at 12 mo, 66/135 at 18 mo, 25/135 at 24 mo) |
| Minni, 201822 | Frontal recess obstruction, synechiae | 9 | NR | Oral abx + steroids, nasal irrigation, topical steroids x 1 mo, weekly debridement as needed. | 9 | 12 |
| Hanci, 202012 | NR | NR | NR | NR | NR | NR |
| Cohort | ||||||
| Friedman, 200823 | turbinate lateralization and scarring | 8 in BSD vs 3 in FESS | NR | NR | 1 in BD vs 0 in FESS | 3 |
| Bozdemir, 201124 | None | 0 | NR | Cefuroxime x 5d, saline irrigations x 2w, topical mometasone spray x 10 mo | 0 | 12 |
| Di Girolamo, 201425 | None | 0 in BSD & ESS | NR | NR | NR | 3 mo (Death @ 3mo: 1 BSD, 5 in ESS)* |
| ElBadawey, 201410 | NR | NR | NR | NR | NR | 3 in prospective group (overall mean 12, range 6 to 24) |
| Koskinen, 202113 | NR | NR | NR | NR | 17 in BSD, 6 in ESS | Mean (min – max) FU in years: BSD: 5.3 (1–11) ESS: 9.8 (5–15) |
| Koskinen, 201726 | Postoperative adhesions not obstructing osteomeatal area | 0 (BSD), 8/38 (ESS) | median sick leave: 4 (2–14 d) in BD vs 14 (9–14) in ESS | debridement in ESS vs none in BSD | NR | Average FU: 52d in BSD (28/36), 33d in ESS (38/39) |
| Koskinen, 201627 | NR | NR | NR | debridement in ESS vs none in BSD | 4 (BSD), 0 (ESS) | 60; mean FU (y): BSD: 6.4 (5.6–7.3), ESS: 6 (4.9–6.9) |
| Koskinen, 201228 | NR | NR | NR | debridement in ESS vs none in BSD | NR | 18 |
| Payne, 201615 | 2 procedure-related events (TIA, dental crown), 1 postop sinus infection | 3 | 2 | care for BSD arm customized to disease process | 0 in BSD, 7/52 (13.5%) in MM had BSD | 6# |
LTFU= lost to follow-up, q.o.w- every other week, gtt-drops, TIA- transient ischemic attack, abx- antibiotics, Sx- surgery, MM-medical management, NR- not reported
*
cause of death unknown
#
Results were reported at longer follow-up of 12 months in an updated publication14